Last reviewed · How we verify
NCT06217211
Eficacia Ventilatoria y Remolacha
NA trial testing Remolacha in SARS CoV 2 Infection in 30 participants. Status unknown.
31 January 2024
Quick facts
| Lead sponsor | Hospital de Mataró |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 13 November 2023 |
| Primary completion | 31 January 2024 |
| Estimated completion | 31 May 2024 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Remolacha
Conditions studied
- SARS CoV 2 Infection — all drugs for SARS CoV 2 Infection →
- Muscle Disorder — all drugs for Muscle Disorder →
- Fatigue — all drugs for Fatigue →
Sponsor
Hospital de Mataró
Who can join
Adults 18 to 75, any sex, with SARS CoV 2 Infection or Muscle Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The lung is the organ most affected by COVID-19. There are patients who successfully overcome the acute COVID-19 infection and their lungs return to a normal state. However, a significant number present dyspnea and fatigue as sequelae without having a pulmonary origin, but with a significant impact on functionality. In our published studies in relation to fatigue in patients with symptoms attributed to persistent COVID, the investigators have shown that there is muscle involvement, observing a decrease in mechanical efficiency. This muscle involvement causes stimulation of ventilation through the ergoreceptors, causing ineffective ventilation. This affectation can be explained by the findings obtained in the muscle biopsies that the investigators have performed, where the investigators observed a splitting of the basement membrane of the capillaries causing an alteration in the diffusion of metabolic substrates and oxygen. The main objective of our project is to be able to observe the response in ventilatory efficiency in patients with symptoms of post-covid fatigue after ingesting beet juice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06217211
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SARS CoV 2 Infection
Currently open trials in the same condition.
- NCT07189936 — Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS · Phase 2 · recruiting
- NCT07197164 — Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients · Phase 2 · recruiting
- NCT06950177 — Pancoronavirus Vaccine Study in Healthy Adults · Phase 1 · active not recruiting
- NCT06640387 — CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools · recruiting
- NCT06633835 — Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United St · Phase 4 · active not recruiting
Other Hospital de Mataró trials
Trials by the same sponsor.
- NCT07192328 — Dose-Efficacy of rTMS in Healthy Young Female Volunteers · NA · completed
- NCT06250426 — Effect of a Cooling Sensation Flavor on the Swallow Response in Post-stroke Patients With Oropharyngeal Dysphagia · NA · unknown
- NCT05958173 — Effects of 6-month of Treatment With TRPV1 and TRPA1 Agonists in Older Patients With OD · NA · unknown
- NCT04739891 — Acute Cholecystitis With Concomitant Choledocholithiasis: Unicentric Study of Prevalence and Predictive Factors · unknown
- NCT04425759 — Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19) · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06217211 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital de Mataró
- Last refreshed: 22 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06217211.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing